PON1Q192R polymorphism is associated with lipid profile in Mexican men with Mayan ascendancy

Experimental and Molecular Pathology

Volumn 85, Issue 2, 2008, Pages 129-134

  Pérez Herrera, Norma ^a   May Pech, Carlos ^b   Hernández Ochoa, Isabel ^a   Castro Mañé, Jorge ^b   Rojas García, Elizabeth ^c   Borja Aburto, Víctor Hugo ^d   Castillo Burguete, Teresa ^e   Quintanilla Vega, Betzabet ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE NAYARIT   (Mexico)

^d INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^e DEPARTAMENTO DE FÍSICA APLICADA   (Mexico)

Author keywords

Atherosclerosis; HDL cholesterol; Lipid profile; PON1 polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PHENYLACETIC ACID;

ADULT; ANAMNESIS; ARTICLE; CROSS-SECTIONAL STUDY; DEMOGRAPHY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HISPANIC; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OXIDATION; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RISK FACTOR;

ADULT; ALLELES; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; GENE FREQUENCY; HOMOZYGOTE; HUMANS; INDIANS, NORTH AMERICAN; LIPIDS; MALE; MEXICO; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 52449100937     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2008.05.003     Document Type: Article

References (47)

1. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol 15 (1995) 1812-1818
2. Ahn Y.I., Valdez R., Reddy A.P., Cole S.A., Weiss K.M., and Ferrel R.E. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatán. Hum. Hered. 41 (1991) 281-289
3. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., and La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1617-1624
4. Bachorik P.S., and Ross J.W. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin. Chem. 41 (1995) 1414-1420
5. Blatter Garin M.C., Moren X., and James R.W. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J. Lipid. Res. 47 (2005) 515-520
6. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., and Furlong C.E. Effects of 5¢ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68 (2001) 1428-1436
7. Cao H., Girard-Globa A., Berthezene F., and Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J. Lipid. Res. 40 (1999) 133-139
8. Chávez-Domínguez R., Ramírez-Hernández J.A., and Casanova-Garces J.M. Coronary heart disease in Mexico and the clinical epidemiological and preventive relevance. Arch. Card. Mex. 73 (2003) 104-114
9. Chen J., Kumar M.W., Chan M., Berkowitz G., and Wetmur J.G. Increased influence of genetic variation on PON1 activity in neonates. Environ. Health Perspec. 111 (2003) 1403-1409
10. Costa L.G., Cole T.B., and Furlong C.E. Polymorphisms of paraoxonase (PON1) and their significance in clinical toxicology of organophosphates. J. Toxicol. Clin. Toxicol. 41 (2003) 37-45
11. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14 (1996) 334-336
12. Deakin S., Leviev I., Nicaud V., Brulhart Meynet M.C., Tiret L., and James R.W. Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families. J. Clin. Endocrinol. Metab. 87 (2002) 1268-1273
13. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 473-480
14. Eckerson H.W., White C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 1126-1138
15. Epidemiological and Death Statistical System/SSA-Yucatán, Mexico. Available at (2006). www.salud.yucatan.gob.mx
16. Fanella S., Harris S.B., Young T.K., Hanley A.J., Zinman B., Connelly P.W., and Hegele R.A. Association between PON1 L/M55 polymorphism and plasma lipoprotein in two Canadian aboriginal populations. Clin. Chem. Lab. Med. 38 (2000) 415-420
17. Ferrel R.E., Kamboh M.I., Majumder P.P., Valdez R., and Weiss K.M. Genetic studies of human apolipoproteins. XIII. Quantitative polymorphism of apolipoprotein C-III in the Mayans of the Yucatán Peninsula. Hum. Hered. 40 (1990) 127-135
18. Flegal K.M., Orden C.L., and Carrol M.D. Prevalence and trends in overweight in Mexican-American adults and children. Nut. Rev. 62 (2004) 144-148
19. Fleiss J.L. Statistical Methods for Rates and Proportions. 2nd Edition (1981), Wiley and Sons, New York
20. Gaidukov L., and Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with apoA-I. Biochemistry 44 (2005) 11843-11854
21. Gamboa R., Zamora J., Rodríguez-Pérez J.M., Fragoso J.M., Cardoso G., Posadas-Romero C., and Vargas-Alarcón G. Distribution of paraoxonase PON1 gene polymorphisms in Mexican populations. Its role in the lipid profile. Exper. Mol. Pathol. 80 (2006) 85-90
22. Geldmacher-von M., Diepgen T.L., Duhme C., and Hommel G. A study of the polymorphism and ethnic distribution differences of human serum paraoxonase. Am. J. Phys. Anthropol. 62 (1983) 235-241
23. Hegele R.A., Brunt H., and Connelly P.W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 89-95
24. Herrera R.J., Rojas D.P., and Terreros M.C. Polymorphic Alu insertions among Mayan populations. J. Hum. Genet 52 (2007) 129-142
25. INEGI. Instituto Nacional de Estadística Geografía e Informática, Secretaría de Salud, Dirección General de Información en Salud. Dirección (2002). http//sinais.salud.gob.mx
26. INI. Instituto Nacional Indigenista. Subdirección de Investigación, Base de localidades y comunidades indígenas. Available at: (1993). http://www.cdi.gob.mx/ini/perfiles/estatal/yucatan/00_resumen.html
27. Ko Y.L., Ko Y.S., Wang S.M., Hsu L.A., Chang C.J., Chu P.H., Cheng N.J., Chen W.J., Chiang C.W., and Lee Y.S. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141 (1998) 259-264
28. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 516-521
29. Li W.-F., Pan M.-H., Chung M.-Ch., Ho Ch.-H., and Chuang H.-Y. Lead exposure is associated with decreased serum paraoxonasa 1 (PON1) activity and genotypes. Environ. Health Perspect. 114 (2006) 1233-1236
30. Lin T.J., Yang D.Y., Jiang D.D., Hung D.Z., Hsu C.L., and Tsai M.S. Relationship of paraoxonase and serum lipids in Taiwan. Kaohsiung J. Med. Sci. 18 (2002) 127-133
31. Mackness B., and Mackness M.I. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?. Free Rad. Biol. Med. 37 (2004) 1317-1323
32. Mackness M.I., Abbott C.A., Arrol S., and Durrington P.N. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem. J. 294 (1993) 829-834
33. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters 423 (1998) 57-60
34. Marra M., Marchegiani F., Antonicelli R., Sirolla C., Spazzafumo L., Olivieri F., Franceschi C., Testa R., Paolisso G., James R.W., Boemi M., and Parati G. The PON1192RR genotype is associated with a higher prevalence of arterial hypertension. J. Hypertens 24 (2006) 1293-1298
35. McGovern P.G., Jacobs Jr. D.R., Shahar E., Arnett D.K., Folsom A.R., Blackburn H., and Luepker R.V. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: The Minnesota Heart Survey. Circulation 104 (2001) 19-24
36. Ombres D., Pannitteri G., Montali A., Candeloro A., Seccareccia F., Campagna F., Cantini R., Campa P.P., Ricci G., and Arca M. The Gln-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1611-1616
37. Primo-Parmo S.L., Sorenson R.E., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is a member of a multigene family. Genomics 33 (1996) 498-509
38. Rojas-García E., Solís-Heredia M.J., Piña-Guzmán B., Vega L., López-Carrillo L., and Quintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol. Appl. Pharmacol. 205 (2005) 282-289
39. Rozek L.S., Hatsukami T.S., Ritcher R.J., Rancláis J., Makayama K., Mckinstry L.A., Gortner D.A., Boyko E., Schellenberg G.D., Furlong C., and Jarvik G.P. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J. Lipid Res. 46 (2005) 1888-1895
40. Sanghera D.K., Saha N., Aston C.E., and Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1067-1073
41. Sentí M., Aubó C., Elosua R., Sala J., Tomás M., and Marrugat J. Effect of physical activity on lipid levels in a population-based sample of men with and without the Arg variant of the human paraoxonase gene. Genet. Epidemiol. 18 (2000) 76-286
42. Serrato M., and Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96 (1995) 3005-3008
43. Singh S., Verma M., Nain C.K., Leelamma C.O., and Goel R.C. Paraoxonase (PON1) polymorphism & its relation with lipids in north west Indian Punjabis. Indian J. Med. Res. 110 (1999) 133-137
44. Sirivarasai J., Kaojarem S., Yoovathaworn K., and Sura T. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects. Chem-Biol. Interac. 168 (2007) 184-192
45. Stone J.J., Bilek S., and Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am. J. Cardiol. 96 (2005) 53-59
46. Tomás M., Sentí M., Elosua R., Vila J., Sala J., Masià R., and Marrugat J. Interaction between the Gln-Arg 192 variants of the paraoxonase gene and oleic acid intake as a determinant of high-density lipoprotein cholesterol and paraoxonase activity. Europ. J. Pharmacol. 432 (2001) 121-128
47. Watson A.D., Navab M., Hama S., Sevanian A., Prescott S.M., Stafforini D.M., McIntyre T.M., Du B.N., Fogelman A.M., and Berliner J.A. Effect of platelet activating factor-acetylhydrolase on the production and activity of mildly oxidized low density lipoprotein. J. Clin. Invest. 95 (1995) 774-782